To recommend endocrine adjuvant treatment, for hormone receptor-positive patients, the panel was asked to choose between ER threshold level ≥1 vs. ≥10% tested by IHC; the panel was equally split 50/50, while 97% of votes recommended endocrine treatment with any tumor size that include microinvasive disease for patients having luminal A and B like lesions. The gene discussed is NR4A1; the disease is neoplasm.